Equities

Integrated Biopharma Inc

INBP:QXR

Integrated Biopharma Inc

Actions
  • Price (USD)0.2232
  • Today's Change0.00 / 0.00%
  • Shares traded5.00
  • 1 Year change--
  • Beta0.7303
Data delayed at least 15 minutes, as of Jun 14 2024 20:40 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Integrated Biopharma Inc. is engaged primarily in manufacturing, distributing, marketing and sales of vitamins, nutritional supplements, and herbal products. The Company’s business segments include Contract Manufacturing operated by Manhattan Drug Company, Inc. (MDC), which manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers and specialized health-care providers; and Other Nutraceutical Businesses, which includes the operations of AgroLabs, Inc. (AgroLabs), The Vitamin Factory (the Vitamin Factory), IHT Health Products, Inc. (IHT), MDC Warehousing and Distribution, Inc., and Chem International, Inc. AgroLabs distributes healthful nutritional products for sale through mass market, grocery and drug and vitamin retailers under the brands: Peaceful Sleep, and Wheatgrass and other products. IHT is a distributor of fine natural botanicals, including multi-minerals produced under a license agreement. Chem is a distributor of raw materials.

  • Revenue in USD (TTM)50.57m
  • Net income in USD-116.00k
  • Incorporated1995
  • Employees141.00
  • Location
    Integrated Biopharma Inc225 Long Ave Ste 15HILLSIDE 07205-2356United StatesUSA
  • Phone+1 (973) 926-0816
  • Fax+1 (973) 926-1735
  • Websitehttps://ir.ibiopharma.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
BioCardia Inc468.00k-10.34m6.21m16.00------13.26-7.04-7.040.3132-1.270.0954--4.4429,250.00-210.81-107.34-1,190.90-154.17-----2,208.76-1,779.24---------64.72-5.262.82---28.89--
GT Biopharma Inc0.00-9.64m6.23m2.00--0.7513-----7.04-7.040.003.850.00----0.00-64.24-205.36-90.39--------------0.00------63.62------
Kineta Inc5.16m-17.89m6.24m11.00------1.21-1.55-1.550.4673-0.5640.6667----469,181.80-230.51-66.16---86.61-----345.77-854.74--------178.6513.8977.76------
Sunshine Biopharma Inc26.74m-4.09m6.25m44.00--0.0132--0.2338-13.35-13.3576.9624.960.90813.1311.58607,722.50-13.88-101.52-17.99-137.0433.1535.47-15.29-165.333.23--0.00--454.42--83.15--110.99--
NuCana PLC (ADR)0.00-33.74m6.34m25.00--0.5312-----301.53-301.530.005.650.00----0.00-72.34-41.01-125.17-48.07------------0.0324------13.71---21.70--
Titan Pharmaceuticals Inc87.00k-4.95m6.34m4.00--1.04--72.93-6.41-6.410.11196.660.0197--1.2321,750.00-112.41-96.80-170.59-156.65-----5,694.25-406.26---415.190.00---66.97-51.1645.43---65.61--
Intelligent Bio Solutions Inc2.83m-10.03m6.42m17.00--0.5392--2.27-64.14-64.144.603.820.20412.697.77166,299.40-72.67-80.65-107.67-224.8423.33---356.09-948.541.87--0.0451--187.51367.97-28.00------
Virios Therapeutics Inc0.00-5.07m6.61m4.00---------0.2673-0.26730.00--------------------------------------56.76------
22nd Century Group Inc29.75m-62.89m6.70m64.00------0.2252-40.02-97.9317.94-3.230.405.905.47464,796.90-66.29-46.78-92.49-54.18-33.09-2.11-165.75-107.950.4284-3.674.76---20.494.03-76.94--53.60--
Integrated BioPharma, Inc.50.57m-116.00k6.72m141.00--0.355231.680.1328-0.0041-0.00411.670.62831.884.4510.76358,617.00-0.43115.51-0.569827.947.0912.09-0.22946.441.02-9.000.001---9.913.00-101.35---14.03--
Kazia Therapeutics Ltd (ADR)14.92k-13.54m6.83m12.00--0.6561--457.55-0.821-0.8210.00080.34950.0007--73.97---63.98-46.35-82.39-54.75-----90,714.45-497.17----0.1297--979.43-28.3118.19------
Actavia Life Sciences Inc0.00-406.65k6.95m1.00---------0.0005-0.00050.00-0.00280.00----0.00-805.97-158.17---------------5.63---------547.04------
Paranovus Entertainment Technology Ltd51.46m-42.62m6.97m80.00--0.6528--0.1355-7.16-7.499.891.461.1859.614.15643,209.90-91.12-23.19-119.36-27.214.9223.09-77.15-24.253.97-2,465.220.00--9.689.80-45.84---21.93--
Pulmatrix Inc11.68m-8.85m7.00m22.00--0.3683--0.5995-2.42-2.423.205.210.3517--17.84531,090.90-26.63-46.91-30.21-58.12-----75.73-238.04----0.00--20.21116.6225.03--104.29--
Viaderma Inc17.80m2.31m7.09m75.000.00030.000021.310.398516.8416.84129.62255.590.412624.691.21237,331.305.36--6.53--28.90--12.99--2.075.660.1718---29.15---40.70------
Data as of Jun 14 2024. Currency figures normalised to Integrated Biopharma Inc's reporting currency: US Dollar USD

Institutional shareholders

0.07%Per cent of shares held by top holders
HolderShares% Held
Moloney Securities Asset Management LLCas of 31 Mar 202420.00k0.07%
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.